You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Contributing to the revenue increase was a rise in in test and collection volume for its thyroid cancer diagnostics.
The firm offered a qualitative assessment of third quarter business activities, and announced a private placement and a US distribution deal with Thermo Fisher.
At its investor day presentation, the company will outline its strategy for accelerating growth and driving operational excellence.
The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.
Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off.
The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests.
The company said revenues from sales of its software services rose more than 250 percent during the quarter.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
The firm reported $6.3 million in third quarter revenues compared to $2.2 million in the year ago period, but fell short of the consensus Wall Street estimate of $7.5 million.
Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.